Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Eurostars project, MTP in situ sequencer, 9877,

Reference number
Funding from Vinnova SEK 7 772
Project duration October 2015 - October 2017
Status Completed
Venture Eurostars

Important results from the project

Together with SU, Olink Bioscience engages in development of in situ sequencing assays that can be used i. a. on the MTP in situ sequencer developed in this project.

Expected long term effects

Spatially resolved multiplexed profiling of biomarkers is expected to improve our understanding of highly heterogenous tissues such as brain as well as shedding light on the biology of complex diseases including cancer. Full automation of in situ sequencing assays is expected to make this spatial profiling technology more accessible to researchers and clinicians who might use in situ sequencing as a diagnostic tool in the future, similar to how simple histological and immunochemical stains are used today.

Approach and implementation

Olink Bioscience has scheduled regular meetings with SU to provide their expertise in development of commercial assays including assay validation and the implementation of quality control routines.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 15 April 2019

Reference number 2015-06132

Page statistics